✦ LIBER ✦

Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study

✍ Scribed by K.A. Papp; A. Menter; B. Strober; R.G. Langley; M. Buonanno; R. Wolk; P. Gupta; S. Krishnaswami; H. Tan; J.A. Harness

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A randomized phase 2a efficacy and safet

✍ Ports, W.C.; Khan, S.; Lan, S.; Lamba, M.; Bolduc, C.; Bissonnette, R.; Papp, K. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 273 KB

Tofacitinib (CP-690,550), an oral Janus

✍ Mamolo, C.; Harness, J.; Tan, H.; Menter, A. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 223 KB

Efficacy and safety of topical janus kin

📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 51 KB

Efficacy and safety of secukinumab in th

✍ Papp, K.A.; Langley, R.G.; Sigurgeirsson, B.; Abe, M.; Baker, D.R.; Konno, P.; H 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 580 KB

A phase I/II randomized, double-blind, p

✍ AK Gupta; C Leonardi; RR Stoltz; PF Pierce; B Conetta; the Ravuconazole onychomy 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 156 KB

Safety and efficacy results of a phase I

✍ Salloway, Stephen; Porsteinsson, Anton; Sperling, Reisa; Keren, Ron; van Dyck, C 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 105 KB